ANAPTYSBIO, INC — Director's Dealing 2018

Dec 5, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ANAPTYSBIO INC (ANAB)
CIK: 0001370053
Period of Report: 2018-12-03

Reporting Person: Piscitelli Dominic (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-12-03	Common Stock	M	37000	$11.34	Acquired	37000	Direct
2018-12-03	Common Stock	S	3554	$70.336	Disposed	33446	Direct
2018-12-03	Common Stock	S	18604	$71.332	Disposed	14842	Direct
2018-12-03	Common Stock	S	4820	$72.2432	Disposed	10022	Direct
2018-12-03	Common Stock	S	2298	$73.1761	Disposed	7724	Direct
2018-12-03	Common Stock	S	6624	$74.33	Disposed	1100	Direct
2018-12-03	Common Stock	S	1100	$75.8091	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-12-03	Employee Stock Option (Right to Buy)	$11.34	M	37000	Disposed	2027-01-07	Common Stock (37000)	Direct

Footnotes

F1: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.

F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.90 to $70.86 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.90 to $71.88 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.91 to $72.90 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.93 to $73.28 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F6: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.00 to $74.95 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.44 to $76.26 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F8: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on January 9, 2018, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

F9: In addition to the remaining options to purchase 133,241 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 98,000 shares of common stock, which options vest according to their terms.